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Material and Methods: A phase II clinical trial was planned 
based on optimal two-stage Simon’s design. Eligibility criteria 
included patients with an Eastern Cooperative Oncology 
Group (ECOG) performance status of ≤3. The primary 
endpoint was to evaluate the symptoms response rate 
produced by a radiotherapy regimen based on the delivery of 
4 radiotherapy fractions (5 Gy per fraction) with a twice daily 
fractionation in two consecutive days. 
 
Results: Twenty-nine patients were enrolled in this trial. 
Characteristics of the patients were: male/female: 16/13; 
median age: 66 years (range: 46-87). ECOG performance 
status was <3 in 25 patients (86.2%). With a median follow-up 
time of 5.0 months (range, 1 to 36 months), 9 G1-2 gastro-
intestinal (31%), 2 G1 haematological (6.8%) and 6 G1 skin 
(20.7%) toxicities were recorded. Only 1 patient (3.4%) 
experienced G3 acute gastro-intestinal toxicity. Of 29 
symptomatic patients, 27 showed an improvement or 
resolution of baseline symptoms (overall palliative response 
rate: 92.6%). Three-month overall survival was 92.2% (median 
survival time: not reached). In 25 patients with pain, a 
significant reduction of this symptom was recorded in terms 
of Drug Score (mean baseline Drug Score vs mean Drug Score 
at follow-up: 5.3 vs 4.0; p=0.04).  
 
Conclusion: Short-course accelerated radiotherapy on 
complicated bone metastases (20 Gy in twice daily fractions 
for 2 consecutive days) is tolerated and effective in terms of 
symptom relief. A phase III comparison against a standard 
palliative regimen (30 Gy in 10 fractions) has been planned in 
this patient population. 
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Purpose or Objective: More than 90% of patients with 
metastatic castration resistant prostate cancer (CRPC) have 
radiologic evidence of bone metastases. Radium-223 
dichloride therapy showed improved overall survival, quality 
of life and symptom control in patients with symptomatic 
bone metastases. Aim of the present study is to evaluate 
clinical course of patients treated in our centre including 
biochemical and imaging response.  
 
Material and Methods: Since November 2014 we started the 
treatment of symptomatic bone metastatic CRPC patients 
with Radium-223 dichloride (50kBq/kg, every 4 weeks). 
Before and after every administration the following 
parameter were recorded: PSA and alkaline phosphatase 
(ALP) values, pain numerical rating scale (NRS), performance 
status (ECOG scale), analgesic therapy and side effects 
(graded according to the CTCAE v. 4 classification). A whole 
body scintigraphy was performed before and one month after 
the treatment.  
 
Results: Twenty patients (total: 70 administrations) were 
treated. All patients showed increased PSA value and reduced 
ALP values. Performance status, evaluated with ECOG scale, 
was improved in all patients. Pain control was excellent, with 
reduction of NRS and analgesic therapies in all patients. Most 
patients showed only G1 toxicity: anaemia (15 pts), fatigue (3 
pts), diarrhea (1 pt), nausea (1 pt), and pain flare-up (6 pts). 
Eight patients completed the 6 planned cycles of therapy. Six 
patients discontinued treatment due to adverse events: 
anaemia (2 pts), pathological fracture of the femur (1 pt), 
severe bleeding (2 pts) and complications in uncontrolled 
diabetes (1 pt). The other patients are still under treatment. 
Whole body scintigraphy performed one month after the end 
of the treatment demonstrated in all patients a reduced 
intensity and number of uptake areas without correlation 
with PSA values. 
 
Conclusion: Treatment with Radium 223 in patients with 
CRPC and symptomatic bone metastases was tolerated in the 
majority of patients. High response rates in terms of 
symptom control and QoL improvement were recorded. 
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Purpose or Objective: To determine the results of 55 
patients with Superior Vena Cava Syndrome (SVCS) treated 
with radiotherapy. 
 
Material and Methods: Between September 2009 and 
September 2014, 55 patients with SVCS were treated at 
Operative Unity of Radiotherapy and Radiobiology, “Hospital 
Pugliese-Ciaccio”, Catanzaro. Of these 21 were women and 
34 men, with a median age at diagnosis of 61 years (range 33-
77 years).The most predominant symptoms were face or neck 
swelling (85%), upper swelling extremity (73%), dyspnea 
(70%), cough (62%), neck and vein distension (45%). 
Radiotherapy (RT) has been the only treatment in 6 of 11 
patients in which the rapidly progressive symptoms has not 
allowed to submit to a histologic diagnosis. For the patients 
which the histo-pathological diagnosis was known and for 
those in which to effect it, the treatment has included both 
the chemotherapy and the radiotherapy. The fractionation 
schedule usually has included initial fractions of 300-400 cGy 
(2-4 fractions) followed by conventional fractionation of 180-
200 cGy. The RT total dose delivered is varied by 2000 cGy to 
5000 cGy 
 
Results: With regard radiotherapy delivered, in 5 (9%) of the 
55 patient essays we have observed a complete regression of 
the SVCS, while in 27 (49%) the response has been partial, 
stability of illness has been underlined in 15 (27%) patients 
and disease progression in 8 (15%) patients. 
 
Conclusion: In summary, in the SVCS the clinical symptoms 
often requires an urgent intervention. Survival depend on the 
status of patient’s disease and on the histologic type of the 
tumor. Radiotherapy is effective in the treatment of the 
initial SVCS and in the patients that relapsed or with 
recurrent illness. The radiotherapy produces a good control 
of the symptoms. There is no necessity of ample fractions in 
the initial treatment. In the reirradiation, the radiotherapy 
on mediastinum is one of the most greater components of the 
palliation. Moreover, in presence laryngeal stridor the 
radiotherapy can be administered before the histological 
diagnosis is available. 
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Purpose or Objective: To evaluate the feasibility and 
effectiveness of combining radiofrequency (RF), 
cementoplasty (CP) and Radiotherapy (RT) for pain treatment 
of bone metastasis (mts) in oligo-metastatic patients (pts). 
 
Material and Methods: From April 2015 to September 2015 
twelve pts. (9 men, 3 women; median age 64 years) with 12 
injuries to bones (vertebral column n = 9; femur, n = 1; 
sacrum, n = 2) were treated. Diagnosis of bone mts and then 
its treatment should be based on the combination of 
different elements: clinical evaluation, CT, MRI and nuclear 
medicine patterns. The mini-invasive treatment of oligo-
metastatic pts aims pain relief that improving the quality of 
life; treat biomechanical stability of the spine; and an 
antineoplastic effect - cytoreductive. RF ablation was 
performed with the pts under sedation a CT - guidance, and 
was followed by cement injection. Pain relief was valuated 
with visual analogue scale (VAS) score. After 10 days on 
average, the patient was subjected to Stereotactic-RT or 
Volumetric Modulated Arc Therapy (VMAT) technique and a 
total dose of 20-30 Gy. 
 
Results: Technical success and pain relief was archived in all 
pts. Pain rating with the VAS decrease from a mean of 9 to a 
mean of 4, and after 3 month was detected a mayor decrease 
(2,5). We recorded an overall improvement in the quality of 
life measured with a suitable test There was no particular 
toxicity. At present no patient died for progression of 
disease.The evolution of the disease will be evaluated with 
the use of MRI.  
 
Conclusion: Our data showing the importance of a multi-
disciplinary approach oligo-metastatic patients. RF with CP 
and RT carried out by experts is effective for pain relief and 
functional recovery in patients with painful bone metastases 
and can significantly improve quality of life. 
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Purpose or Objective: Few phase II trials have been 
performed to analyse the efficacy of post-operative 
stereotactic ablative radiotherapy (SABR) for brain 
metastases. The aim of the present study was to analyse 
outcome of this strategy in another cohort. 
 
Material and Methods: Between September 2011 and 
February 2015 a total of 49 patients (49 lesions) were treated 
and available for analysis. Eligibility criteria included 
histologically confirmed malignancy with 1 intra parenchymal 
brain metastase, age ≥18 years, Karnofsky performance 
status (KPS) ≥70 and controlled extracranial disease. Fourt y-
two patients have been treated with a single fraction of 18 
Gy, and 7 patients with 5 fractions of 5-7 Gy (median dose of 
31 Gy) if tumor size was more than 3 cm. SABR treatment 
was prescribed to the 80% isodose. Survival was evaluated 
with the Kaplan Meier method. 
 
Results: The median follow-up was 14 months (range, 2-45). 
SABR to the surgical bed was performed 41 days (13-105) 
after surgery. Overall, there were 8 local failures (LF) 
resulting in a 6 months, 1- and 2-year local control rates of 
97.9%, 86%, and 74.9%, respectively. The 1- and 2-year 
overall survival rates were 62.6% and 39%. The 6 months, 1- 
and 2-year encephalic control rates were 72.9%, 56.7%, and 
34.6%, respectively. The Biological Effective Dose, histology, 
and time interval between surgery and SABR did not correlate 
with LF in univariate analysis (p> 0.05, Log-Rank).Tumor 
maximal diameter >3 cm was associated with an increased 
rate of LF in comparison with smaller tumors (one-year rate 
LF of 30% vs 7.1%, p=0.02, Log-Rank). Seventy percent of 
patients died because of extra cranial disease progression 
while 30 % of patient because of intracranial disease 
progression. For 14patients with multiple recurrent brain 
metastases, the whole brain radiotherapy was performed 294 
days (126-812) after SABR. 
 
Conclusion: In this cohort postoperative SABR was associated 
with high rates of local control and encephalic tumor control, 
especially for brain metastases <3 cm. 
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Purpose or Objective: Unstable spinal metastases require 
surgical stabilization often followed by radiotherapy for local 
tumor control. However, surgical stabilization and 
radiotherapy are not very compatible treatment modalities. 
A frequent complication of surgical stabilization after 
irradiation is disturbed wound healing which can have a 
devastating impact on quality of life. Advancements in 
surgical techniques has led to the development of less 
invasive surgical (LIS) procedures. LIS procedures aim to 
achieve similar clinical outcomes, as compared with open 
procedures, but with less approach related morbidity. 
Additionally, improved wound healing after LIS procedures 
may allow earlier administration of adjuvant treatments. 
However, little is known concerning the complications after 
LIS procedures for the treatment of spinal metastases. 
Therefore the aim of this study was to determine the 
incidence and characteristics of complications after 
percutaneous pedicle screw fixation (PPSF) for the treatment 
of unstable spinal metastases. 
 
Material and Methods: An ambispective multicentre cohort 
study of patients who underwent PPSF between 2009 and 
2014 for the treatment of unstable spinal metastases was 
performed. Data regarding demographics, tumor histology, 
surgical treatment, neurological status, complications and 
survival were systematically collected. 
 
Results: A total of 101 patients were identified, 45 males and 
56 females with a mean age of 60.3 years (± 11.2). The most 
common primary tumors (in hierarchical order) were breast 
cancer (25%), multiple myeloma (25%), lung cancer (13%) and 
renal cell carcinoma (10%). Ninety-three per cent of the 
patients were neurologically intact at the time of surgery. 
The median operating time was 122 minutes (range 55 – 325) 
with a median blood loss of 100 ml (N=41). The overall 
median survival was 11.0 months (range 0-70 months) with 79 
(78%) patients being alive three months postoperative. 
Eighty-seven per cent of the patients was ambulatory within 
three days postoperative. A total of 30 complications 
occurred in 18 patients. Non-surgical adverse events (9%) 
were most commonly encountered. Wound complications 
occurred in 4 patients, including 2 deep wound infections 
with one requiring surgical debridement. Prolonged operating 
was associated with increased risk of post-operative 
complications (P=0.041). No relation between the 
administration of pre- or postoperative radiotherapy and the 
occurrence of complications could be determined. 
 
